CPAP-Compliance of Aging Individuals with Obstructive Sleep Apnea With or Without Mild Cognitive Impairment by Carter, Bailey
The University of Maine 
DigitalCommons@UMaine 
Honors College 
Spring 5-2020 
CPAP-Compliance of Aging Individuals with Obstructive Sleep 
Apnea With or Without Mild Cognitive Impairment 
Bailey Carter 
University of Maine, 16bcarter@gmail.com 
Follow this and additional works at: https://digitalcommons.library.umaine.edu/honors 
 Part of the Cognitive Neuroscience Commons, and the Sleep Medicine Commons 
Recommended Citation 
Carter, Bailey, "CPAP-Compliance of Aging Individuals with Obstructive Sleep Apnea With or Without Mild 
Cognitive Impairment" (2020). Honors College. 583. 
https://digitalcommons.library.umaine.edu/honors/583 
This Honors Thesis is brought to you for free and open access by DigitalCommons@UMaine. It has been accepted 
for inclusion in Honors College by an authorized administrator of DigitalCommons@UMaine. For more information, 
please contact um.library.technical.services@maine.edu. 
 
 
CPAP-COMPLIANCE OF AGING INDIVIDUALS WITH OBSTRUCTIVE SLEEP 
APNEA WITH OR WITHOUT MILD COGNITIVE IMPAIRMENT 
by 
Bailey B. Carter 
 
 
 
A Thesis Submitted in Partial Fulfillment 
of the Requirements for a degree with Honors 
(Zoology) 
 
 
 
 
The Honors College 
University of Maine 
May 2020 
 
 
 
 
 
 
 
Advisory Committee: 
Marie Hayes, Professor of Psychology, Advisor 
Thane Fremouw, Associate Professor of Psychology and Psychology  
Department Chair 
Clarissa Henry, Associate Professor of Biological Sciences 
Leonard Kass, Associate Professor of Biological Sciences 
Jordan LaBouff, Associate Professor of Psychology and Honors 
 
 
ABSTRACT 
 
 
 
With approximately 20% of Americans affected by obstructive sleep apnea 
(OSA), and over 30% of sleep apneic patients non-compliant with the most common 
form of treatment, CPAP (Continuous Positive Airway Pressure), the proposed study 
looks to investigate the relationship between OSA, CPAP-compliance, and cognitive 
decline associated with many aging-related neurodegenerative diseases [1, 2]. Our group 
has performed in-home sleep studies using a patented, sensor mattress-sheet device, and 
standard actigraphy. Demographics including a questionnaire on OSA compliance and 
neurocognitive tests were administered to participants between 62 and 90 years of age. 
Cognitive decline meeting criteria for MCI (Mild Cognitive Impairment, the prodrome of 
Alzheimer’s Disease) were determined, and groups were made of comparison individuals 
(n=45) and MCI individuals (n=50). CPAP compliance in relationship to MCI diagnosis 
was examined. It was hypothesized that there would be a correlation between CPAP-
compliance of OSA participants and increased cognitive functioning, compared to the 
CPAP noncompliant counterparts. The proposed mechanism consists of sleep disruption 
for the CPAP noncompliant group, which would cause chronic hypoxia and decreased 
restorative function of sleep in the brain and other organs during sleep. The results show 
that participants with OSA compared to those where were non-OSA were significantly 
more likely to have identifiable comorbid conditions: higher BMI (p=0.026), 
hypertension (p=0.003), hypercholesterolemia (p=0.035), diabetes (p=0.015), and current 
depressive symptoms (p=0.042). The OSA group was also more likely to be male than 
the non-OSA group, (p=0.016). Additionally, the OSA group was found to have more 
 
 
sleep impairments compared to non-OSA: higher PSQI sum composite score (p=0.02), 
higher PSQI daytime dysfunction score (p=0.02), and decrease in sleep quality duration 
(p=0.01). Lastly, the OSA group performed significantly worse on the neurocognitive 
BVMT-R recognition of false alarms compared to the non-OSA group (p=0.002). CPAP-
compliance was also found to be significantly associated with less comorbid health 
conditions and many sleep quality assessments. CPAP noncompliance was associated 
with hypertension (p=0.006), more current depressive symptoms (p=0.035), and diabetes 
(p=0.025), compared to the CPAP-complaint group. The CPAP-compliant group was 
found to have many significant associations with sleep measures compared to the CPAP 
noncompliant group: increased sleep quality (p=0.03), decreased sleep disturbances 
(p=0.02), decreased daytime dysfunction (p=0.03), improved PSQI sum composite score 
(p=0.03), and increased habitual sleep efficiency (p=0.05). There were no conclusive 
results between CPAP-compliance and neurocognitive assessment. 
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INTRODUCTION 
Obstructive Sleep Apnea (OSA) 
Obstructive sleep apnea (OSA) is defined as a medical condition that has the 
reoccurring collapse of the airway by relaxation of the upper airway muscles during sleep 
[3]. The collapse of the airway causes breathing to pause intermittently, decrease air 
passage, and increase carbon dioxide levels in the blood [4]. Clinically, apnea is defined 
by the cessation of breathing, with at least 5 cessations per hour, and an increasing 
number of cessations indicates higher severity [4]. The apnea-hypopnea index (AHI) has 
been created to categorize the severity of a patient’s OSA, from mild, moderate, and 
severe for 5, 15, and ≥ 30, respectively [5]. The increasing number of apneas means that 
the body is without air for a greater period of time every hour. This air provides the 
oxygen needed for the cardiopulmonary system to oxygenate the brain and the periphery. 
However, the collapse of the airway during sleep diminishes this process. This repeated 
collapse causes hypoxemia, or deoxygenation of the bodily tissues, during sleep [6]. It is 
hypothesized that chronic hypoxemia during sleep will cause significant cognitive 
decline, as hypoxia of the brain is a known factor for cognitive decline and 
neurodegeneration [7]. Beyond the effects of hypoxia, OSA causes increased arousals 
during sleep, increased sleep fragmentation, and diminished sleep quality every night [8. 
This lack of sleep can lead to sleep deprivation, and eventually the risk of MCI [9]. 
There is increasingly more research into understanding cognitive decline and its 
lead to MCI and eventual Alzheimer’s Disease (AD). Sleep disruption has been an 
interesting point to highlight in recent years, as it is thought that it may impede the 
restorative function of sleep. Individuals with OSA have documented sleep disturbances 
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and suffer from nocturnal intermittent hypoxia, both of which have been hypothesized to 
cause cognitive impairment [10–12]. Through these proposed mechanisms of sleep 
disorder associated with OSA-related intermittent hypoxia, it is proposed that individuals 
with OSA would show signs of cognitive impairment. Other studies have looked to 
investigate this relationship as well, and while there is yet to be a consensus around a 
solidified mechanism, persons with OSA have been found to have decreased cognitive 
assessment scores and more likely to have a cognitive impairment, as seen through MCI 
and AD [13]. While there is some variation in the proposed mechanisms for these 
associations, there is an increasing evidence of dual sleep fragmentation and intermittent 
hypoxia epidemiology [13–15]. Between the detrimental effects on the process of sleep 
itself, including less sleep overall and a lower quality of sleep with sleep fragmentation, 
and the fact that the body can be hypoxic for a non-insignificant portion of the night, 
OSA can be seen to be a truly debilitating disease that can diminish the brain’s cognitive 
abilities. 
Continuous Positive Airway Pressure (CPAP) 
One of the most common treatments for OSA is continuous positive airway 
pressure (CPAP). CPAP works by blowing a continuous stream of air into the airway, 
through the mouth and or nasal passages [16]. There are two major types of CPAP masks, 
an oral-nasal covering or a nasal mask, and the type of mask is dependent on the patient’s 
preferences and physiology. The air from these masks pushes against the relaxed 
muscles, increasing the opening of the airway and allowing for more air to reach the 
remainder in the cardiopulmonary system. This air is often humidified for increased 
compliance and does not have a direct oxygen input, as from a tank or concentrator, and 
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simply takes the air from the patient’s surroundings. While this is the standard practice 
for treating OSA, it does not come without its difficulties.  
CPAP-compliance is a constant problem with those who use this form of 
treatment. Some studies have shown that over one-third of patients who are prescribed 
CPAP are not compliant in its use [17]. While there is a wide spectrum over what is 
deemed as CPAP-compliant, such as 4-6 hours per night, or for at least 3-5 nights per 
week, this study’s compliance metric was for CPAP use for at least 4 hours a night [17]. 
While some of these machines do have the functionality to internally record CPAP-
compliance metrics, primarily for billing purposes, this information is often not 
standardly released to each patient. CPAP is well known for its uncomfortable nature, 
and that the air forced into the body can be quite distressing. This causes many of these 
patients to either use CPAP for only a few nights per week or a handful of hours per 
night. 
Low CPAP-compliance is most often due to the unwanted side effects of wearing 
a CPAP mask, such as it being uncomfortable when strapped onto the head and the 
feeling of the air being blown into the airway. While nasal CPAP machines may be less 
uncomfortable compared to their oral-nasal counterparts, there are still uncomfortable 
side effects in most CPAP masks. While there are other treatment options for OSA, such 
as mouth guards and surgical options, questions on alternative treatment options on the 
participant survey. What is most interesting about CPAP effectiveness is its effects on 
intermittent hypoxia and sleep fragmentation. CPAP has shown not only to increase 
blood oxygen levels but also to decrease the effects of sleep fragmentation [18]. Since 
these two symptoms of OSA are treated through CPAP, it is reasonable to suspect that 
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CPAP-compliance may increase cognitive function from the previously mentioned 
mechanisms. While this project can not study the direct effects of CPAP-compliance on 
cognitive status, we hope to gain a better understanding of the possible association 
between OSA, CPAP-compliance and cognitive decline. 
Metabolic Syndrome (MS) 
 Metabolic syndrome (MS) is defined as the common comorbidity of various 
cardiovascular and endocrine diseases, including hypertension, diabetes, 
hypercholesterolemia, and obesity [19, 20]. While there are a number of proposed 
mechanisms for metabolic syndrome, the leading theory states that MS may be from the 
body’s increased lipid levels, and thus leading to insulin resistance over time [20–22]. 
Beyond the typical mechanism for cardiovascular diseases and hypertension in the body 
associated with a high BMI, this hyperlipidemia leads to hypertension, thus further 
propagating negative cardiovascular effects [22, 23].  
With these vast, yet intricate systems constantly interworking amongst each other, 
the effects of OSA can have a crippling double-down effect on both the endocrinological 
and cardiovascular system. When OSA is added to this already taxed body system, the 
corresponding effects, known as Syndrome Z, can lead to further distress and 
complications [24]. About 60% of people with metabolic syndrome have Syndrome Z, 
and CPAP used to treat the OSA components of Syndrome Z have shown to decrease 
several of the symptoms of MS [25]. Studies have shown independent effects of OSA on 
both diabetes or cardiovascular disease. Not only has OSA and diabetes been found to be 
associated with an increasing prevalence of each other, but some hypotheses claim that 
they could be linked through the impacts of intermittent hypoxia on the endocrine 
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systems of the body, leading to symptoms like insulin resistance [26]. Although we have 
already well established the link between OSA and cardiovascular diseases, other studies 
have also shown that intermittent hypoxia causes additional stress on the cardiovascular 
system via increases irregular arousal of the sympathetic nervous system, inflammation, 
and oxidative stress onto the body [27–29]. Between these two already prevalent 
interconnected diseases, it appears that OSA could be the connecting point helping to 
cause further exacerbation of these conditions and increased disease severity.  Many of 
the conditions that make up MS were recorded during the participant demographic 
questionnaire of this study. By further identifying the comorbid conditions of OSA, we 
hope to further investigate the role of OSA in turning metabolic syndrome into the more 
complicated and dangerous, Syndrome Z. 
Mild Cognitive Impairment (MCI) 
Between the large number of individuals who have OSA and these individuals not 
being CPAP-compliant, there is an increasing number of people who have decreased 
oxygen perfusion while sleeping. This study investigated the relationship between OSA, 
CPAP-compliance, and cognitive decline. Cognitive decline was measured between 
individuals with Mild Cognitive Impairment (MCI) and those with normal cognition. 
MCI is defined as cognitive decline that is greater than expected for an individual’s age 
and education level without significantly impairing daily living [30]. This cognitive 
decline is seen with both crystallized intelligence, knowledge, and skills learned over 
one’s life, and fluid intelligence, complex thinking with problem-solving and reasoning, 
to some extent [31]. While crystallized intelligence remains strong up to our 60s-70s, on 
average, fluid intelligence begins to decline after our 30s, and both can be measured and 
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seen to decline with neurocognitive testing as we age [31]. These forms of intelligence 
can help serve as markers to judge the form of MCI. MCI can be broadly separated into 
two groups, amnestic and non-amnestic MCI, memory or cognitive abilities associated 
with normal functioning such as speaking and mental tasks, respectively [32].  However, 
these two forms of MCI can make diagnosis and assessment difficult, as they affect 
different parts of one’s cognitive abilities and thus may cause some confusion in trying to 
fully understand one’s MCI diagnosis. Since MCI is so broad, it can relay a spectrum of 
symptoms that are unique to each patient. These symptoms can range from difficulty 
remembering basic facts like names, to confusion, or difficulty with complex tasks such 
as balancing a checkbook or driving. While patients with MCI can have clear and 
noticeable symptoms, they are still able to function mostly independently and live on 
their own. It is not until the disease progresses to a more advanced state that a further 
diagnosis of AD is established, and these patients are unable to live by themselves.  After 
initial MCI diagnosis, cognitive decline can be quite rapid, with up to 15% of MCI 
patients progressing into an AD diagnosis every year [33]. While MCI can be diagnosed 
by electronic or paper assessments, AD is diagnosed through a much more significant 
cognitive decline. This diagnosis requires more advanced diagnostic tools, including MRI 
and serum analysis, with patients who are often noted with biomarkers including 
increased beta-amyloid plaques and tau proteins [34]. While the underlying mechanism 
connecting OSA and AD are not fully understood, nocturnal intermittent hypoxia and 
sleep disruption seem to be a promising opportunity. CPAP treatment is seen as a 
plausible route to reducing neurocognitive decline and AD symptoms [35]. 
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Hypotheses 
1. Aging individuals with Obstructive Sleep Apnea (OSA) will have:  
a. higher incidence of comorbid health conditions compared to those who do 
not have OSA (non-OSA).  
b. more sleep problems through subjective sleep measures and show poorer 
sleep quality in actigraphy, compared to non-OSA.  
c. aging participants with OSA will perform worse on neurocognitive 
assessments than non-OSA.  
 
2.  Amongst the OSA group, those who are CPAP-compliant (CPAP-compliant) 
compared those who are not (CPAP noncompliant): 
a. CPAP noncompliant are less likely to have comorbid health conditions 
b. CPAP-compliant group will show higher sleep quality, through actigraphy 
and self-report than OSA CPAP noncompliant groups. 
c. CPAP-compliant group will perform better on neurological assessments 
compared to the CPAP noncompliant group. 
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METHODS 
 
Participants 
In order to collect the data needed for this research, a standardized set of IRB 
approved procedures and protocols were followed to recruit participants, set up 
equipment, record their data and analyze their results amongst our expert panel. 
Participants, aged 62 and 90 years old, were first recruited in the greater Orono/Bangor, 
Maine and then areas in southern Maine.  
Recruitment 
This was done in the local community through methods such as local news 
reports, flyers, the University of Maine Center on Aging registry, presentations to senior-
living facilities, and peers of past participants. This community group made up the 
original comparison group for our study, or those that were not known to have any 
neurodegenerative disorders (e.g. MCI, AD, etc.). Initially, all participants with cognitive 
decline and impairment were introduced through neurological consult, Dr. Cliffod Singer, 
MD, of Northern Light Acadia Hospital in Bangor, Maine, or from the University of New 
England, Legacy Scholars registry under Dr. Thomas Meuser with scores of 1 or 2 on an 
AD-8 prescreen. These participants were clinically diagnosed with MCI or pre-screened 
to likely have MCI. These were participants that made up the MCI group.  
One of the problems faced during this study was finding enough participants to 
meet the predetermined threshold for MCI. In order to reach the quota specified in the 
study, the participant recruitment was expanded from just Bangor, Maine to Southern and 
central Maine. Additional participants were flagged as potentially MCI participants due 
to scores on neurocognitive assessments. After a thorough assessment of their data and 
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consideration by the expert panel, including C. Singer, M.D.; F. Ahmed, Ph.D.; M. Elias, 
Ph.D.; and J. Aronis, M.A., some control participants were deemed to have cognitive 
impairment and were transferred into the MCI category. 
Assessment Measures 
The actigraphy device used for this study was the Philips Respironics Actiwatch 
2, the ‘gold-standard’ in actigraphy assessment. It is a small device worn on the 
participant's nondominant wrist for 7 consecutive days. This device measured movement 
of participant sleep/wake and has shown to have significant and meaningful results 
regarding the movements of aging adults [36]. 
 During the first visit, participants were asked to complete a comprehensive 
demographics questionnaire, Center for Epidemiological Studies Depression Scale (CES-
D), Montreal Cognitive Assessment (MoCA) and self-report sleep questionnaires 
(Epworth Sleepiness Scale (ESS), the Stanford Sleepiness Scale (SSS), and Consensus 
Sleep Diary). 
The second visit consisted of neurocognitive assessments, testing many facets of 
participant neurocognitive health, within 30 days. These neurocognitive measures 
included the Hopkins Verbal Learning Test-Revised (HVLT-R), Trails Making Test A 
and B, Brief Visuospatial Memory Test-Revised (BVMT-R), and the Boston Naming 
Test. 
 
Statistical Analyses 
An independent-samples t-test (continuous variables) and a chi-square test of 
association (categorical variables) were conducted to compare physiological demographic 
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measures of the OSA group,  non-OSA group, CPAP-compliant group, and CPAP 
noncompliant group. 
 
Sleep Study Protocol 
The protocol used during this research project was a part of a larger IRB-
approved study. The methods used and participant experience was standardized to 
minimize potential biases. The sleep study protocol was separated into two main 
components, the first-visit mattress-sheet set-up, and the follow-up neurocognitive 
assessment. However, before individuals could participate in the study, they were pre-
screened through an intake interview that would ensure that they fit the guidelines set by 
the initial study. The inclusionary criteria included but were not limited to, being within 
the predetermined age range mentioned above, and having the ability to live 
independently and perform most of their own tasks. Most of these inclusionary criteria 
fell within this broader scope of if the patient could live and work independently and did 
not need a professional caretaker to assist them. The reason for these criteria was to help 
exclude patients with more serious neurodegenerative disorders from the study. There 
were numerous other criteria, but they also included basic components that included non-
AD individuals, being non-bedridden, and not being able to take care of their daily tasks 
and activities, independently, as well as having no additional possible causes of MCI (e.g. 
poorly controlled diabetes, more than one cerebral infarct, REM sleep disorder, etc.). 
After determining that the individuals were qualified to be a part of the study, participants 
scheduled their first home visit. 
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First visits were a crucial step in the study in building relationships with our 
participants and to further assess participants on their individual situations. After arriving 
at the participant homes, participants would complete a demographics questionnaire, 
which included a list of prescribed medications and a detailed examination of their 
medical history. There were additional questionnaires used to screen for current and 
historical depression, which included the Center for Epidemiological Studies Depression 
Scale (CES-D) [37]. After this, a participant interview was conducted including a 
cognitive prescreen, Montreal Cognitive Assessment (MoCA), and a subjective sleep 
measure, Pittsburgh Sleep Quality Index [38,39]. Sleep quality and daytime sleepiness 
were measured using the Epworth Sleepiness Scale (ESS), the Stanford Sleepiness Scale 
(SSS), and Consensus Sleep Diary, with the latter two being continued over the next 
seven days [40–42]. 
After this, the patented mattress-sheet device, SleepMove, was then shown to the 
participants and set up on their bed. The mattress-sheet device is a thin sheet embedded 
with flat wired sensors that detect movements and respiration during sleep. Participants 
were instructed to sleep directly on this device for the next two nights as they would 
normally. Participants were also instructed to wear an Actiwatch on their non-dominant 
wrist for seven days. The Actiwatch measured patient actigraphy data, including 
movement and basic motor activity, and was used to help determine wakefulness and 
sleep patterns.  
Within 30 days of the initial visit, the research team returned to the participant 
homes to conduct an in-depth neurocognitive assessment. This assessment included the 
Hopkins Verbal Learning Test-Revised (HVLT-R), Trails Making Test A and B, Brief 
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Visuospatial Memory Test-Revised (BVMT-R), and the Boston Naming Test [43–46]. 
These tests assessed a wide range of participant cognitive abilities, including item 
recognition, brief and long-term recall, and pattern recognition. 
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RESULTS 
 
Hypothesis 1a 
Aging individuals with Obstructive Sleep Apnea (OSA) (OSA group) will have a 
higher incidence of comorbid health conditions compared to those who do not are non-
OSA. 
There was a significant sex difference among OSA vs. non-OSA groups; X2(1, 
N=95), p=0.016. Males were more likely to have OSA than females. The OSA group was 
significantly more likely to have comorbid conditions such as high BMI, X2(1, N=90), 
p=0.026; hypertension, X2(1, N=92), p=0.003, hypercholesterolemia, X2(1, N=93), 
p=0.035, diabetes, X2(1, N=93), p=0.015, and current depressive symptoms,  X2(1, 
N=93), p=0.042. These results are demonstrated in Table 1 below. Table 1 depicts the 
demographic data of the OSA and non-OSA, and any significant associations found. 
Table 1. Demographic information table for OSA and non-OSA groups 
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Hypothesis 2a 
OSA participants who are in the CPAP-compliant group were less likely to have 
comorbid health conditions than OSA participants who were in the CPAP noncompliant 
group.  
An independent-samples t-test (continuous variables) and a chi-square test of 
association (categorical variables) were conducted to compare physiological demographic 
measures with the CPAP-compliant group and the CPAP noncompliant group. The CPAP 
compliant group were less likely to have comorbid conditions such as hypertension 
between OSA groups; X2(1, N=92), p=0.006, current depressive symptoms; X2(1, N=93), 
p=0.035, and diabetes, X2(1, N=93), p=0.025. 
Hypothesis 1b 
OSA group participants will report having more sleep problems through 
subjective sleep measures and poorer sleep quality through actigraphy, compared to non-
OSA.  
 An Independent-samples t-test was conducted to compare sleep measures of the 
OSA group and non-OSA group. For sleep measures, OSA group had a significantly 
higher composite score for the PSQI (M=8.19, SD= 4.59), compared to non-OSA 
(M=6.00, SD=3.31); t(91) = -2.43, p = 0.02. This result is displayed in Figure 1, and 
shows a significant difference in PSQI sum composite scores for the OSA and non-OSA 
group. For sleep quality measures, higher scores indicate that the individual has poorer 
sleep quality. In addition, OSA group had significantly higher scores for daytime 
dysfunction on the PSQI (M=1.04, SD= 1.03), compared to non-OSA (M=0.583, 
SD=0.746); t(91)=-2.297, p = 0.02. This analysis is demonstrated in Figure 2, as the 
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PSQI assessment 7 - daytime dysfunction is shown to be significantly different between 
the OSA and non-OSA groups. Finally, there was also a significant difference in the 
scores for sleep quality duration for the OSA group (M=1.11, SD= 0.910), compared to 
non-OSA (M=0.67, SD=0.69); t(91)=-2.58, p = 0.01. 
 
 
                 
Figure 1. PSQI Sum Composite Score      Figure 2. PSQI Daytime Dysfunction  
 by OSA group       by OSA group 
 
 
Finally, sleep actigraphy showed no differences in the suite of sleep quality 
measures listed in Table 2. Table 2 lists measured actigraphy movement data between 
OSA and non-OSA groups, and zero significance was found for any variable.  
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                   Table 2. Actigraphy results for OSA and non-OSA groups 
 
 
Hypothesis 2b 
The CPAP compliant group compared to the CPAP noncompliant group will 
record with less impairment in sleep questionnaires (subjective sleep) or actigraphy 
(objective sleep).  
An Independent-samples t-test was conducted to compare sleep measures of the 
CPAP-compliant group and the CPAP noncompliant group. There was a significant 
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difference in the scores for subjective sleep quality for the CPAP-compliant group 
(M=0.56, SD= 0.53), compared to CPAP noncompliant (M=1.33, SD=0.89); t(19)=-2.33, 
p = 0.03. A higher score is indicative of having a poorer subjective sleep quality. 
Additionally, there was a significant difference in the scores for sleep disturbances for 
CPAP-compliant (M=1.11, SD= 0.33), compared to the CPAP noncompliant participants 
(M=1.58, SD=0.52); t(18.70)=2.55, p = 0.02. A significant difference was also found  in 
the scores for PSQI assessment 7 - daytime dysfunction for CPAP-compliant group 
(M=0.56, SD= 0.53), compared to the CPAP noncompliant (M=1.42, SD=1.16); 
t(16.17)=2.27, p = 0.03.  
 The sum composite PSQI score for CPAP-compliant group(M=5.89, SD= 2.52), 
was significantly lower compared to the CPAP noncompliant (M=9.92, SD=5.11); 
t(16.87)=-2.37, p = 0.03. Both of these analyses have been plotted on Figures 3 and 4, to 
show the significant difference found between the CPAP-compliant and CPAP 
noncompliant groups for PSQI sum composite score and PSQI assessment - 7 daytime 
dysfunction, respectively. Finally, the scores for habitual sleep efficiency for CPAP-
compliant were trending towards a significant difference (M=0.56, SD= 0.88), compared 
to the CPAP noncompliant groups (M=1.58, SD=1.38); t(18.65)=2.077, p = 0.052. For 
the measures listed above, a higher score denotes increased impairment. 
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Figure 3. PSQI Sum Composite Score              Figure 4. PSQI Daytime Dysfunction 
  by CPAP-compliance group                              by CPAP-compliance group 
 
 
 
Hypothesis 3a 
The OSA group will perform more poorly on neurocognitive assessments than the 
non-OSA group. 
An Independent-samples t-test was conducted to compare neurocognitive testing 
measures between the OSA and non-OSA groups. There was a significant difference in 
the scores for BVMT-R recognition false alarms for the OSA group (M=0.053, SD= 
0.23), compared to the non-OSA group (M=0.42, SD=0.79); t(81.99)=3.27, p = 0.002. A 
higher score indicated more impairment and that more false alarms on figure recognition 
occurred. This result is seen in Figure 5, as the non-OSA group has significantly more 
false alarm recognitions in the BVMT-R than the OSA group. A false alarm is defined as 
when a participant incorrectly chooses a newly displayed figure as being previously 
shown earlier in the assessment, even though it has not. The BVMT-R assesses visual 
 
 
19 
 
learning and memory, and the false alarms show that the OSA group has some deficits in 
either visual learning or memory compared to non-OSA. Since the OSA group did not 
remember and therefore incorrectly identified the displayed figures, it helps to 
demonstrate that the OSA group has some form of cognitive impairment compared to the 
non-OSA group. 
 
Figure 5. BVMT-R Recognition False Alarms Raw Score               
 OSA group 
 
Hypothesis 3b 
The CPAP-compliant group will perform with less impairment on neurocognitive 
testing compared to the CPAP noncompliant group. 
An Independent-samples t-test was conducted to compare neurocognitive testing 
measures for the CPAP-compliant group and the CPAP noncompliant group. There were 
no statistically significant results to report for CPAP compliance and neurocognitive 
exam measures.  
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DISCUSSION 
 
Previous studies have shown that OSA and comorbid health conditions, especially 
cardiovascular diseases, are significantly associated [36, 37]. Another comorbid condition 
is metabolic syndrome, which affects the cardiovascular and endocrine systems. This 
association is especially prevalent in obese individuals [49]. Our results confirm most of 
what has been previously researched regarding OSA and chronic health conditions. The 
data shows a significant association between the OSA group and the increased likelihood 
of a participant having hypertension, hypercholesterolemia, diabetes, higher BMI, and 
current depressed mood. The results are in line with the metabolic syndrome associated 
with OSA stated previously, as well as literature on OSA and diabetes [38, 41, 42]. Our 
data agrees with the previously found results that males are more likely to have OSA than 
females, which also agrees with current literature [4, 39]. While the direct cause of this is 
still unknown, perhaps it could be linked to the average distribution of adipose in adults. 
With men having adipose tissue deposited more centrally around the trunk compared to 
women, perhaps this could cause for airway obstruction during sleep [51]. While our 
results were not significant between OSA and thyroid disease, and OSA and diabetes, 
studies have shown a significant association between OSA and diabetes [52,53].  
OSA is known and well studied, to be linked to decreased sleep quality through 
numerous testing measures. While our data only showed a significant difference for PSQI 
daytime dysfunction and composite score, OSA has also been linked to measures such as 
decreased sleep efficiency, increased daytime sleepiness, sleep fragmentation and 
reduced daytime wakefulness [53].The PSQI is a subjective sleep measure where the 
participant rates their own sleep quality, with more disturbed sleep earning a higher PSQI 
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score. Our findings for a higher sum composite PSQI score is not uncommon, as PSQI 
scores have shown to be significantly higher for OSA individuals in past studies [54]. 
The proposed cause for decreased sleep quality for OSA individuals is believed to come 
from sleep disruption from OSA’s breathing pauses and hypoxemia during sleep [53]. 
This nocturnal hypoxia cycle is thought to be the cause of decreased cognitive 
abilities of OSA individuals [55]. There are a number of studies linking OSA and 
neurocognitive decline, and most of them reference this intermittent night hypoxia as the 
plausible mechanism [55,56]. Although there are numerous measures to record cognitive 
decline, with both subjective and objective options, our study only found significant 
results with BVMT-R. The BVMT-R is a neurocognitive measure that measures 
visuospatial memory and tests the participant's ability to remember and identify a series 
of figures. While our data only found significant differences for BVMT-R recognition 
false alarms for the OSA group, other studies have shown a significant difference in total 
recall [56]. For this data set, the OSA group had significantly more false alarms, meaning 
that the participants incorrectly stated that an example figure was previously displayed, 
when it actually was not shown. 
Although CPAP compliance is still the most successful therapy for OSA, CPAP 
continues to have low compliance for CPAP. The CPAP-compliant group showed 
decreased risk for comorbid conditions such as hypertension, current depressive 
symptoms, and diabetes. While using a CPAP mask may cause a large percentage of 
users to not adhere to the treatment, those who do, report much higher sleep quality. In 
this study, OSA individuals who were CPAP compliant recorded significantly higher 
subjective sleep quality, fewer sleep disturbances, less daytime dysfunction, and a lower 
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composite PSQI score. Studies have shown that CPAP use improves sleep quality, sleep 
efficiency, and sleep duration [57]. These findings further support the idea that CPAP-
compliance has many positive impacts on sleep quality. While the means for these results 
show CPAP-compliance as having a lower integer for sleep measures, this still shows that 
CPAP-compliance increases positive sleep characteristics, as higher scores denote more 
impairment and worsening sleep measures. 
While our data did not display any significant findings between neurocognitive 
assessment and CPAP-compliance, this could be due to a number of factors that must be 
considered. First, our sample size for CPAP-compliance was only 22, which can make it 
difficult to find statistical significance. Current research shows conflicting results 
regarding the effects of  CPAP-compliance on neurocognitive abilities and assessments 
[58–61]. One of the reasons for this could be due to the complexity and difficulty 
assessing the vast array of cognitive abilities that the brain possesses, and the numerous 
cognitive assessments that are used throughout the scientific community. 
While actigraphy was a significant component of the data collection and analysis, 
there were no significant results found for either OSA or CPAP groups. This could be due 
to several factors, including only having seven days of wrist actigraphy data available. 
Even when the length of wrist actigraphy was increased in other studies to 2+ weeks, 
there was still conflicting data regarding OSA and CPAP compliance [62,63]. Some 
studies have had multiple weeks of data and were unable to find any significance with 
actigraphy, thus it may be even more difficult to find significance with our 7 days worth 
of actigraphy data. Also, as actigraphy devices are worn on the wrists of participants, it 
may not be able to fully detect sleep disruptions occurring in the upper third of the body. 
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While the chest and neck may be moving during sleep disruption, the wrist may not move 
to any significant extent, and thus not record any meaningful results. 
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CONCLUSION 
 
 The goal of this thesis project was to investigate the relationship between OSA 
and compliance with its most common form of treatment, CPAP, and the possible effects 
on sleep and neurocognitive status. Through the use of demographics questionnaires, 
actigraphy, a novel mattress-sheet device, subjective sleep assessment, and 
neurocognitive examination, data was collected and analyzed. The initial hypothesis 
suggested that there would be significant decreases in sleep and neurocognitive status 
compared between OSA and non-OSA participants, as well as CPAP noncompliant vs. 
CPAP-compliant groups. Our results indicated that individuals were at an increased risk 
of having OSA if they had a high BMI, hypercholesterolemia, hypertension, diabetes, 
current depressed mood and if they were a male. This supports the first proposed 
hypothesis, that the OSA group would have more comorbid conditions than the non-OSA 
group. OSA group also had significant findings for having poorer subjective sleep 
quality, through having a higher PSQI sum composite score and having a higher score or 
PSQI 7 - daytime dysfunction. This increase in score denoted a higher impairment in 
sleep quality. It was also found that the OSA group were more likely to record false 
alarms on the BVMT-R, thus signaling a possible neurocognitive deficit. These OSA 
findings were predicted and supported through previous research studies. While these 
results do have some support for the OSA hypotheses initially stated in the study, there 
were only significant findings for a small number of examinations out of the many that 
were administered. 
 This study also investigated the relationship between CPAP-compliance and 
participant health. We found that the CPAP-compliant group were at lower risk for 
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hypertension, diabetes, and current depressed mood. Additionally, it was found that the 
CPAP-compliant group had better subjective sleep quality, fewer sleep disturbances, 
decreased daytime dysfunction, and lower sum composite scores on the PSQI compared 
to CPAP noncompliant group. All of these results suggest support for the original 
hypothesis that the CPAP-compliant group would have better sleep health. However, this 
study did not support its last hypothesis and failed to find any neurocognitive benefits of 
CPAP-compliance. 
 While we found mixed results in supporting our initial hypotheses, we had zero 
significant findings regarding actigraphy with any of our participant data. However, 
previous studies have shown that it can be difficult to have significant findings with 
actigraphy, especially with only 7 days worth of data. Our study has other limitations that 
could have affected our findings. First, we had a relatively low N for OSA and CPAP-
compliance groups (N=22). Additionally, the demographics questionnaires administered 
offered little insight into further patient history of OSA and CPAP-compliance. There 
was no severity index for participant OSA, such as the well known apnea-hypopnea index 
(AHI), and the demographics information only included a ‘yes/no’ option for physician-
diagnosed OSA. Similarly, patients were not asked about their CPAP-compliance in 
depth. CPAP-compliance has a vague and un-agreed upon meaning not only for lay 
individuals but for the scientific community as a whole.  
Future studies would benefit greatly from more precise demographics 
information, especially regarding OSA and CPAP-compliance. While this study did have 
its limitations, there were several significant findings that support some of our initial 
hypotheses and previous research studies. Most importantly, it helps to further bolster the 
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importance of early detection and diagnosis of OSA and increased use in CPAP mask 
treatment, by demonstrating the many negative consequences surrounding both OSA and 
CPAP noncompliance. Furthermore, this study helps support why we should increase 
resources to public health programs to educate the populace on OSA and the ever-
increasing importance of using CPAP treatment. Finally, this study has helped us to learn 
more about the new novel sleep study mattress-sheet device and the possibility for in-
home sleep studies. It is believed that these in-home sleep studies will one day help 
replace current sleep study methods inside sleep clinics, as participants are able to get a 
more ‘normal’ and complete rested sleep within the confines of their own bedrooms. 
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